Particularly Hazard Substance Drug
Drugs not found on the list, yet having special acute or chronic hazards (e.g., carcinogenecity, teratogenecity), require development of an SOP. Contact EH&S for assistance.
Drug |
AHFS classification |
Reason for listing |
Links |
abacavir* |
8:18.08.20 nucleoside and reverse transcriptase inhibitors |
FDA Pregnancy Category C; malignant tumors observed in male and female mice and rats; genotoxic in in vivo micronucleus test. |
DailyMed; DrugBank |
abiraterone* |
10:00 antineoplastic agents |
Women who are pregnant or women who may be pregnant should not handle without protection (e.g., gloves); FDA Pregnancy Category X |
DailyMed; DrugBank |
acitretin |
88:04 vitamin A |
Black Box warning on adverse reproductive effects; FDA Pregnancy Category X |
DailyMed; DrugBank |
ado- trastuzumab emtansine |
10:00 antineoplastic agents |
Conjugated monoclonal antibody; FDA Pregnancy Category D |
DailyMed; DrugBank |
alefacept |
84:92 skin and mucous membrane agents, miscel- laneous |
Increased frequency of malignancies observed in treated patients; FDA Preg- nancy Category B |
DailyMed; DrugBank |
alitretinoin |
84:92 skin and mucous membrane agents, miscel- laneous |
FDA Pregnancy Category D |
DailyMed; DrugBank |
altretamine |
10:00 antineoplastic agents |
FDA Pregnancy category D |
DailyMed; DrugBank |
ambrisentan |
24:12:92 vasodilating agents, miscellaneous |
Black Box warning on adverse reproductive effects; reduced sperm counts in patients; FDA Pregnancy Category X |
DailyMed; |
amsacrine |
NA antineoplastic agents |
IARC Group 2B |
DrugBank |
anastrozole |
10:00 antineoplastic agents |
FDA Pregnancy category X |
DailyMed; DrugBank |
apomorphine |
28:36.20.08 Nonergot- derivative dopamine receptor agonists |
FDA Pregnancy Category C; genotoxic in several in vitro assays. |
DailyMed; DrugBank |
arsenic trioxide |
10:00 antineoplastic agents |
IARC Group 1 carcinogen**; FDA Pregnancy Category D |
DailyMed; DrugBank |
azacitidine |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
azathioprine |
92:44 immunosuppressant agents |
IARC Group 1 carcinogen**; FDA Pregnancy Category D*** |
DailyMed; DrugBank |
bacillus calmette Guerin (BCG)*** |
80:12 vaccines |
See special handling requirements**; FDA Preg- nancy Category C |
DailyMed |
bendamustine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; |
bexarotene |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; DrugBank |
bicalutimide |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; DrugBank |
bleomycin |
10:00 antineoplastic agents |
IARC Group 2B; FDA Preg- nancy Category D |
DailyMed; DrugBank |
bortezomib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
bosentan |
24:12:92 vasodilating agents, miscellaneous |
Black Box warning on adverse reproductive effects; FDA Pregnancy Category X |
DailyMed; DrugBank |
brentuximab vedotin |
10:00 antineoplastic agents |
Conjugated monoclonal antibody; FDA Pregnancy Category D |
DailyMed; DrugBank |
busulfan |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
cabazitaxel |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
cabergoline |
28:36:20:04 ergot-derivative dopamine receptor agonists |
Inhibition of conception and embryo fetal effects at doses below recommended human dose; FDA Pregnancy Cate- gory B |
DailyMed; DrugBank |
capecitabine |
10:00 antineoplastic agents |
Metabolized to 5-fluoro- uracil; FDA Pregnancy Cate- gory D |
DailyMed; DrugBank |
carbamazepine |
28:12:92 anticonvulsants, miscellaneous |
Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy |
DailyMed; Drugbank |
carboplatin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
carmustine |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
cetrorelix |
92:40 gonadotropin- releasing hormone anago- nists |
FDA Pregnancy Category X |
DailyMed; DrugBank |
chlorambucil |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
chloramphenicol |
8:12:08 chloramphenicols |
IARC Group 2A carcinogen; FDA Pregnancy Category C |
DailyMed; DrugBank |
choriogonado- tropin |
68:18 gonadotropins |
FDA pregnancy Category X; may cause fetal harm when administered to a pregnant woman. |
DailyMed; DrugBank |
cidofovir |
8:18:32 nucleoside and nucleotides |
FDA Pregnancy Category C |
DailyMed; Drugbank |
cisplatin |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
cladribine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
clofarabine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
clonazepam |
28:12:08 benzodiapines |
Increased risk of congenital abnormalities when taken in first trimester; FDA Pregnancy Category D |
DailyMed; DrugBank |
colchicine |
92:16 antigout agents |
FDA Pregnancy Category C; published animal reproduc- tion and development studies indicate it causes embryofetal toxicity, teratogenicity, and altered postnatal develop- ment at exposures within or above the clinical therapeutic range |
DailyMed; DrugBank |
crizotinib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed |
cyclophospha- mide |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; Drugbank |
cyclosporine |
92:44 immunosuppressive agents |
IARC Group 1 carcinogen; FDA pregnancy Category C |
DailyMed; Drugbank |
cytarabine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
dacarbazine |
10:00 antineoplastic agents |
FDA Pregnancy Category C |
DailyMed; Drugbank |
dactinomycin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
dasatinib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; Drugbank |
daunorubicin |
10:00 antineoplastic agents |
IARC Group 2B, AKA dauno- mycin; FDA Pregnancy Cat- egory D |
DailyMed; Drugbank |
decitabine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; Drugbank |
deferiprone |
64:00 Heavy metal antagonists |
Genotoxic in vitro and in vivo; FDA Pregnancy |
DailyMed; DrugBank |
degarelix |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; Drugbank |
dexrazoxane |
92:56 protective agents |
FDA Pregnancy Category C; secondary malignancies observed in patients treated long term with Razoxane (a racemic mixture containing dexrazane); genotoxic in vitro and in vivo; in labo- ratory studies, testicular atrophy observed at or below the human dose |
DailyMed; DrugBank |
diethylstilbestrol |
NA |
IARC Group 1 carcinogen; FDA Pregnancy Category X |
DrugBank |
dinoprostone |
76:00 oxytocics |
Hazardous only for women in late pregnancy; FDA Preg- nancy Category C |
DailyMed; DrugBank |
divalproex |
28:12:92 anticonvulsants, miscellaneous |
Black Box warning for tera- togenicity; FDA Pregnancy Category D; tumors seen in laboratory studies at doses below MRHD |
DailyMed |
docetaxel |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
doxorubicin |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
dronedarone |
24:04:04 antiarrythmics |
Teratogenic in laboratory studies at ½ MRHD; FDA Preg- nancy Category X |
DailyMed; DrugBank |
dutasteride |
92:08 5-alpha reductase inhibitors |
Women warned not to handle; FDA Pregnancy Cate- gory X |
DailyMed; DrugBank |
entecavir |
8:18:32 nucleosides and nucleotides |
FDA Pregnancy Category C |
DailyMed; DrugBank |
epirubicin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; Drugbank |
ergonovine/meth- ylergonovine |
76:00 oxytocics |
Use is contraindicated during pregnancy because of its uterotonic effects; FDA Preg- nancy Category C |
DailyMed; DrugBank; DrugBank |
eribulin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
erlotinib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
estradiol |
68:16:04 estrogens |
DailyMed; DrugBank |
|
estramustine |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; Drugbank |
estrogen/ progesterone combinations |
68:12 contraceptives |
DailyMed |
|
estrogens, conjugated |
68:16:04 estrogens |
DailyMed |
|
estrogens, esterified |
68:16:04 estrogens |
DailyMed |
|
estropipate |
68:16:04 estrogens |
DailyMed; DrugBank |
|
etoposide |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
everolimus |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; Drugbank |
exemestane |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; DrugBank |
finasteride |
92:08 5-alpha reductase inhibitors |
Women should not handle crushed or broken finasteride tablets when they are preg- nant or may potentially be pregnant due to potential risk to a male fetus; FDA Preg- nancy Category X |
DailyMed; Drugbank |
fingolimod |
92:20 biologic response modifiers |
DailyMed; DrugBank |
|
floxuridine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
fluconazole |
8:18.08 azoles |
FDA Pregnancy Category C; case reports describe con- genital anomalies in infants exposed in utero to maternal fluconazole (400-800 mg/ day) during most or all of the first trimester, similar to those seen in animal studies |
DailyMed; DrugBank |
fludarabine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
fluorouracil |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
fluoxymesterone |
68:08 androgens |
Tumors in mice and rats and possibly humans; FDA Preg- nancy Category X |
DailyMed; DrugBank |
flutamide |
10:00 antineoplastic agents |
Indicated only for men; FDA Pregnancy Category D |
DailyMed; DrugBank |
fosphenytoin |
28:12.12 hydantoins |
Metabolized to phenytoin; FDA Pregnancy Category D |
DailyMed; DrugBank |
fulvestrant |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
ganciclovir |
8:18:32 nucleosides and nucleotides |
FDA Pregnancy Category C |
DailyMed; DrugBank |
ganirelix |
92:40 gonadotropin- eleasing hormone antagonists |
FDA Pregnancy Category X |
DailyMed |
gemcitabine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
gemtuzumab ozogamicin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
gonadotropin, chorionic |
68:18 gonadotropins |
Defects of forelimbs and central nervous system and alterations in sex ratio have been reported in laboratory studies; FDA pregnancy Cat- egory C |
DailyMed; DrugBank7 |
goserelin |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; Drugbank |
hydroxyurea |
10:00 antineoplastic agents |
Special warning on handling bottles and capsules |
DailyMed; DrugBank |
icatibant |
92:32 complement inhibitors |
FDA Pregnancy Category C; in laboratory studies, prema- ture birth and abortion rates increased at a dose that was less than 1/40th the MRHD and delayed parturition and fetal death occurred at 0.5 and 2-fold, respectively, the MRHD |
DailyMed; DrugBank |
idarubicin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
ifosfamide |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
imatinib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
irinotecan |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
ixabepilone |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
leflunomide |
92:36 disease-modifying antirheumatic agents |
Teratogenic in laboratory studies at 1/10 HD; marked postnatal survival at 1/100 HD; FDA Pregnancy Cate- gory X; severe liver injury reported in patients; carcino- genicity observed at doses below HD |
DailyMed; DrugBank |
lenalidomide |
92:20 biologic response modulators |
Analog of thalidomide; FDA Black box warnings for limb abnormalaties; pregnancy Cat- egory X; in laboratory studies, caused thalidomide-type limb defects in monkey offspring |
DailyMed; DrugBank |
letrozole |
10:00 antineoplastic agents |
FDA pregnancy Category X |
DailyMed; DrugBank |
leuprolide |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; Drugbank |
liraglutide recombinant |
68:20.06 incretin mimetics |
FDA Pregnancy Category C; Black Box warning for thy- roid C-cell tumors, with supporting evidence in lab- oratory studies; also in labo- ratory studies, teratogenic at or below the MRHD. |
DailyMed; DrugBank |
lomustine |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
mechloreth- amine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
medroxyproges- terone acetate |
68:32 progestins |
IARC Group 2B; FDA Preg- nancy Category X |
DailyMed; DrugBank |
megestrol |
10:00 antineoplastic agents |
Nursing should be dis- continued if megestrol is required. Women at risk of pregnancy should avoid exposure; FDA Pregnancy Category X |
DailyMed; DrugBank |
melphalan |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
mentropins |
68:18 gonadotropins |
FDA Pregnancy Category X |
Drugbank |
mercaptopurine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
methotrexate |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed; DrugBank |
methyltestos- terone |
68:08 androgens |
FDA Pregnancy Category X |
DailyMed; DrugBank |
mifepristone |
76:00 oxytocics |
When given to pregnant women results in termination of pregnancy; FDA Pregnancy Category X |
DailyMed; DrugBank |
misoprostol |
56:28.28 prostaglandins |
FDA Pregnancy Category X |
DailyMed; DrugBank |
mitomycin |
10:00 antineoplastic agents |
IARC Group 2B; FDA Preg- nancy Category D |
DailyMed; DrugBank |
mitotane |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
mitoxantrone |
10:00 antineoplastic agents |
IARC Group 2B; FDA Preg- nancy Category D |
DailyMed; DrugBank |
mycophenolate mofetil |
92:44 immunosuppressive agents |
DailyMed; DrugBank |
|
mycophenolic acid |
92:44 immunosuppressive agents |
DailyMed; DrugBank |
|
nafarelin |
68:18 gonadotropins |
Note: Given only as nasal spray; no potential for occu- pational exposure; FDA Preg- nancy Category X |
DailyMed; DrugBank |
nelarabine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
nevirapine |
8:18.08.16 nonnucleoside reverse transcriptase inhibitors |
DailyMed; DrugBank |
|
nilotinib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
omacetaxin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
oxaliplatin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
oxcarbazepine |
28:12:92 anticonvulsants, miscellaneous |
DailyMed; Drugbank |
|
oxytocin |
76:00 oxytocics |
Hazardous only for women in 3rd trimester; FDA Pregnancy Category C |
DailyMed; DrugBank |
paclitaxel |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
palifermin |
84:16 cell stimulants and proliferants |
DailyMed; Drugbank |
|
paroxetine |
28:16:04:20 selective sero- tonin uptake inhibitors |
Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in third trimester; FDA Preg- nancy Category D |
DailyMed; Drugbank |
pazopanib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
pemetrexed |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
pentetate calcium trisodium |
NA |
Severe teratogenic effects in laboratory studies in dogs: supplied in ampule which can lead to occupational exposure; FDA Pregnancy Category C |
DailyMed |
pentostatin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
phenoxyben- zamine |
12:16:04:04 non-selective alpha-andrenergic blocking agents |
DailyMed; DrugBank |
|
phenytoin |
28:12.12 hydantoins |
DailyMed; DrugBank |
|
pipobroman |
NA |
Drugbank |
|
plerixafor |
20:16 hematopoietic agents |
Teratogenic in laboratory studies; FDA Pregnancy Cate- gory D |
DailyMed; DrugBank |
pralatrexate |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
procarbazine |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
progesterone |
68:32 progestins |
DailyMed; Drugbank |
|
progestins |
68:12 contraceptives |
||
propylthiouracil |
68:36.08 antithyroid agents |
DailyMed; DrugBank |
|
raloxifene |
68:16:12 estrogen ago- nists-antagonists |
DailyMed; Drugbank |
|
rasagiline |
28:36 antiparkinsonian agents |
DailyMed; Drugbank |
|
ribavirin |
8:18:32 nucleosides and nucleotides |
Teratogenic and embryotoxic effects in several laboratory studies; contraindicated in women who are pregnant and in the male partners of women who are pregnant; FDA Pregnancy Category X |
DailyMed; DrugBank |
risperidone |
28:16:08:04 atypical anti- psychotics |
DailyMed; DrugBank |
|
romidepsin |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed |
sirolimus |
92:44 immunosuppressive agents |
DailyMed; DrugBank |
|
sorafenib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
spironolactone |
24:32.20 mineralocorticoid receptor antagonists |
FDA Pregnancy Category C; black box warning for tumorogenicity in laboratory studies. |
DailyMed; DrugBank |
streptozocin |
10:00 antineoplastic agents |
IARC Group 2B; FDA Preg- nancy Category D |
DailyMed; DrugBank |
sunitinib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
tacrolimus |
92:44 immunosuppressive agents |
Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk; FDA Pregnancy Cate- gory C |
DailyMed; DrugBank |
tamoxifen |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
telavancin |
8:12:28 glycopeptides |
Black Box warning for poten- tial risk to fetus and adverse reproductive outcomes; reduced fetal weights and increased rates of digit and limb malformations in three species at clinical doses; FDA Pregnancy Category C |
DailyMed; Drugbank |
temozolomide |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
temsirolimus |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
teniposide |
10:00 antineoplastic agents |
IARC Group 2A carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
testosterone |
68:08 androgens |
Children should avoid contact with unwashed or unclothed application sites on skin; FDA Pregnancy Category X |
DailyMed; DrugBank |
thalidomide |
92:20 biologic response modulators |
FDA Pregnancy Category X |
DailyMed; DrugBank |
thioguanine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
thiotepa |
10:00 antineoplastic agents |
IARC Group 1 carcinogen; FDA Pregnancy Category D |
DailyMed; DrugBank |
topiramate |
28:12.92 anticonvulsants, miscellaneous |
FDA Pregnancy Category D |
DailyMed; DrugBank |
topotecan |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
toremifene |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
tretinoin |
84:16 cell stimulants and proliferants |
Black Box warning for severe birth defects; Special FDA dis- tribution system; FDA Preg- nancy Category X |
DailyMed; DrugBank |
trimetrexate |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
triptorelin |
10:00 antineoplastic agents |
FDA Pregnancy Category X |
DailyMed |
ulipristal |
68:12 contraceptives |
FDA Pregnancy Category X |
DailyMed |
uracil mustard |
NA |
FDA Pregnancy Category D |
DrugBank |
valganciclovir |
8:18:32 nucleosides and nucleotides |
FDA Pregnancy Category C |
DailyMed; DrugBank |
valproate/valproic acid |
28:12:92 anticonvulsants, miscellaneous |
Black Box warning for terato- genicity; congenital malfor- mations including neural tube defects and others; terato- genic in multiple species; FDA Pregnancy Category D |
DailyMed; DailyMed; DrugBank |
valrubicin |
10:00 antineoplastic agents |
FDA Pregnancy Category C |
DailyMed; DrugBank |
vandetanib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
vemurafenib |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
vigabatrin |
28:12:92 anticonvulsants, miscellaneous |
Malformations seen in labora- tory studies below the MRHD; FDA Pregnancy Category C |
DailyMed; Drugbank |
vinblastine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
vincristine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; Drugbank |
vinorelbine |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; DrugBank |
voriconazole |
8:14.08 azoles |
FDA Pregnancy Category D |
DailyMed; DrugBank |
vorinostat |
10:00 antineoplastic agents |
FDA Pregnancy Category D |
DailyMed; Drugbank |
warfarin |
20:12.04.08 coumarin derivatives |
FDA Pregnancy Category D |
DailyMed; DrugBank |
zidovudine |
8:18:08 antiretroviral agents |
IARC Group 2B; FDA Preg- nancy Category C |
DailyMed; DrugBank |
ziprasidone |
28:16:08:04 atypical antipsychotics |
Developmental toxicity, including possible terato- genic effects at doses similar to human therapeutic doses; an increase in the number |
DailyMed; Drugbank |
zoledronic acid |
92:24 bone resorption inhibitors |
Number of stillbirths increased and survival of neo- nates decreased in laboratory studies at low doses; FDA Pregnancy Category D |
DailyMed; DrugBank |
zonisamide |
28:12:92 anticonvulsants, miscellaneous |
Teratogenic in multiple animal species; FDA Preg- nancy Category C |
DailyMed; DrugBank |